Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT03267654 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG: gefitinib combined with chemotherapy
DRUG: gefitinib combined with apatinib
DRUG: gefitinib single agent

Sponsor

Qilu Pharmaceutical Co., Ltd.